Drug intelligence / Profile preview

TML-OTE-18-I

Development stage: Preclinical
Lead developer: Themis Medicare
Modality: Drug Delivery Systems, Small Molecules

Overview

TML-OTE-18-I is a preclinical-stage pharmaceutical candidate being developed by Themis Medicare. It is classified as a non-steroidal anti-inflammatory drug (NSAID) and utilizes a Novel Drug Delivery System (NDDS). While the specific active pharmaceutical ingredient has not been disclosed, the drug is designed to leverage advanced formulation technology to potentially enhance the delivery, safety, or efficacy of the NSAID component. As an NSAID, its primary therapeutic application is expected to be the management of pain and inflammatory conditions through the inhibition of cyclooxygenase enzymes.

Targets

COX

Beyond the preview

Go deeper on TML-OTE-18-I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TML-OTE-18-I.

Explore the full profile